Skip to main content

Advertisement

SpringerLink
Log in

Verteporfin

  • New Drug Profile
  • Adis New Drug Profile
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

  • ▲ Verteporfin, a benzoporphyrin derivative monoacid ring A, is a photosensitising drug for photodynamic therapy (PDT) activated by low-intensity, nonheat-generating light of 689nm wavelength. Activation generates cytotoxic oxygen free radicals.

  • ▲ The specificity and uptake of verteporfin for target cells with a high expression of low density lipoprotein (LDL) receptors, such as tumour and neovascular endothelial cells, is enhanced by the use of a liposomal formulation and its rapid uptake by plasma LDL.

  • ▲ Verteporfin therapy (at light doses < 150 J/cm2) selectively damages neovascular endothelial cells leading to thrombus formation and specific occlusion of choroidal neovascular vessels in subfoveal lesions in patients with age-related macular degeneration (AMD).

  • ▲ Repeated applications of verteporfin therapy 6 mg/m2 improved or maintained visual acuity in the majority of patients with some classic subfoveal choroidal neovascularisation (CNV) secondary to AMD at 1 year’s follow-up in 2 large multicentre, placebocontrolled, double-blind trials.

  • ▲ Furthermore, in a subgroup of these patients with predominantly classic CNV secondary to AMD, there was a significantly more marked visual acuity (VA) benefit with 67.3% of verteporfin-treated eyes experiencing less than a 15-letter loss of VA versus 39.3% with placebo treatment.

  • ▲ Multiple applications of verteporfin therapy were well tolerated in patients with subfoveal CNV secondary to AMD. The most common adverse events were visual disturbances, injection site reactions, photosensitivity reactions and infusion-related back pain.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Klein R, Klein B, Linton K. Prevalence of age-related maculopathy. Ophthalmology 1992; 99: 933–43

    PubMed  CAS  Google Scholar 

  2. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy: selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996 Mar; 103: 427–38

    PubMed  CAS  Google Scholar 

  3. Husain D, Miller JW. Photodynamic therapy of exudative age-related macular degeneration. Semin Ophthalmol 1997; 12(1): 14–25

    Article  Google Scholar 

  4. Schmidt-Erfurth U, Birngruber R, Hasah T. Photodynamic therapy in ocular vascular disease. Laser Physics 1998; 8: 191–8

    CAS  Google Scholar 

  5. Fine SELL. Photodynamic therapy with verteporfin is effective for selected patients with neovascular age-related macular degeneration. Arch Ophthalmol 1999; 117: 1400–2

    Google Scholar 

  6. Levy JG. Photosensitizers in photodynamic therapy. Semin Oncol 1994 Dec; 21 Suppl. 15: 4–10

    PubMed  CAS  Google Scholar 

  7. Richter AM, Waterfield E, Jain AK, et al. In vitro evaluation of phototoxic properties of four structurally related benzoporphyrin derivatives. Photochem Photobiol 1990 Sep; 52: 495–500

    Article  PubMed  CAS  Google Scholar 

  8. Richter A, Sternberg E, Waterfield E, et al. Characterisation of benzoporphyrin derivative, a new photosensitiser. Adv Photochemother 1988; 997: 132–8

    Google Scholar 

  9. Richter AM, Waterfield E, Jain AK, et al. Photosensitising potency of structural analogues of benzoporphyrin derivative (BPD) in a mouse tumour model. Br J Cancer 1991 Jan; 63: 87–93

    Article  PubMed  CAS  Google Scholar 

  10. Allison BA, Pritchard PH, Levy JG. Evidence for low-density lipoprotein receptor-mediated uptake of benzoporphyrin derivative [published erratum appears in Br J Cancer 1995 Jan; 71 (1): 214]. Br J Cancer 1994 May; 69: 833–9

    Article  PubMed  CAS  Google Scholar 

  11. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-delivered benzoporphyrin. Arch Ophthalmol 1995 Jun; 113: 810–8

    Article  PubMed  CAS  Google Scholar 

  12. Husain D, Miller JW, Michaud N, et al. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996 Aug; 114: 978–85

    Article  PubMed  CAS  Google Scholar 

  13. Schmidt-Erfurth U, Hasan T, Gragoudas E, et al. Vascular targeting in photodynamic occlusion of subretinal vessels. Ophthalmology 1994 Dec; 101: 1953–61

    PubMed  CAS  Google Scholar 

  14. Lin SC, Lin CP, Feld JR, et al. The photodynamic occlusion of choroidal vessels using benzoporphyrin derivative. Curr Eye Res 1994 Jul; 13: 513–22

    Article  PubMed  CAS  Google Scholar 

  15. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in cynomolgus monkey. Ophthalmology 1999; 106: 1915–23

    Article  PubMed  CAS  Google Scholar 

  16. Schmidt-Erfurth U, Miller J, Sickenberg M, et al. Photodynamic therapy of subfoveal choroidal neovascularization: clinical and angiographic examples. Graefes Arch Clin Exp Ophthalmol 1998 May; 236: 365–74

    Article  PubMed  CAS  Google Scholar 

  17. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularisation by age-related macular degeneration: results of a single treatment in a phase I and 2 study. Arch Ophthalmol 1999; 117: 1161–73

    Article  PubMed  CAS  Google Scholar 

  18. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy with verteporfin for choroidal neovascularisation caused by age-related macular degeneration: results of retreatment in a phase 1 and 2 study. Arch Ophthalmol 1999; 117: 1177–87

    Article  PubMed  CAS  Google Scholar 

  19. Allison BA, Pritchard PH, Richter AM, et al. The plasma distribution of benzoporphyrin derivative and the effects of plasma lipoproteins on its biodistribution. Photochem Photobiol 1990 Sep; 52: 501–7

    Article  PubMed  CAS  Google Scholar 

  20. Richter AM, Waterfield E, Jain AK, et al. Liposomal delivery of a photosensitizer, benzoporphyrin derivative monoacid ring A (BPD), to tumour tissue in a mouse tumour model. Photochem Photobiol 1993 Jun; 57: 1000–6

    Article  PubMed  CAS  Google Scholar 

  21. Treatment of Age-related Macular Degeneration with Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularisation in age-related macular degeneration with verteporfin. Arch Ophthalmol 1999; 117: 1329–45

    Google Scholar 

  22. Ciba Vision. Regulatory submissions. Viewpoint 1999 (News on the developments in photodynamic therapy): 3

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 10, New Zealand

    Lesley J. Scott & Karen L. Goa

Authors
  1. Lesley J. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen L. Goa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lesley J. Scott.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scott, L.J., Goa, K.L. Verteporfin. Drugs & Aging 16, 139–146 (2000). https://doi.org/10.2165/00002512-200016020-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200016020-00005

Keywords

Search

Navigation